26462-22-6

Basic information

• Product Name: H-ILE-LEU-OH
• Synonyms: L-ISOLEUCYL-L-LEUCINE;L-ILE-L-LEU;H-ILE-LEU-OH;L-Leucine, L-isoleucyl-
• CAS NO: 26462-22-6
• Molecular Formula: C12H24N2O3
• Molecular Weight: 244.33
• Mol File: 26462-22-6.mol

Chemical Properties

• Boiling Point: 432.7±30.0 °C(Predicted)
• Appearance: /
• Density: 1.051±0.06 g/cm3(Predicted)
• Storage Temp.: -15°C
• PKA: 3.16±0.10(Predicted)
• CAS DataBase Reference: H-ILE-LEU-OH(CAS DataBase Reference)
• NIST Chemistry Reference: H-ILE-LEU-OH(26462-22-6)
• EPA Substance Registry System: H-ILE-LEU-OH(26462-22-6)

Safety Data

• Hazardous Substances Data: 26462-22-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Applications:
H-ILE-LEU-OH is used as a therapeutic agent for inhibiting movement-induced muscle damage and muscle defective conditions. It works by targeting specific pathways involved in muscle function and repair, providing relief and support for individuals suffering from muscle-related issues.
Used in Sports Medicine:
In the sports medicine industry, H-ILE-LEU-OH is used as a performance enhancer and muscle recovery aid. It helps to reduce muscle damage and improve overall muscle function, making it a valuable supplement for athletes and individuals engaged in regular physical activity.
Used in Research and Development:
H-ILE-LEU-OH is also utilized in research and development for its potential applications in various fields, including pharmacology, biotechnology, and neuroscience. Its unique properties and interactions with biological systems make it an interesting compound for further study and potential drug development.

Upstream product

• 61543-27-9 N-tert-butoxycarbonyl-L-isoleucyl-L-leucine methyl ester 
• 13139-16-7 N-(tert-butyloxycarbonyl)-L-isoleucine 
• 2343-74-0 N-trifluoroacetyl-L-isoleucyl-L-leucine methyl ester 
• 759-78-4 (2S,3S)-3-methyl-2-(2,2,2-trifluoroacetamido)pentanoic acid 
• 2666-93-5 (S)-Leu-OMe 
• 35661-60-0 Fmoc-Leu-OH 
• 71989-23-6 Fmoc-Ile-OH 
• 4818-03-5 Z-L-Ile-L-Leu-OMe 
• 3160-59-6 N-Cbz-L-Isoleucine 
• 38972-95-1 N-Benzyloxycarbonyl-L-isoleucyl-L-leucin 
• 328-39-2 LEUCINE 
• 86382-33-4 2-bromo-3-methyl-valeryl chloride 

Relevant articles and documents

Synthesis of L-leucyl-L-isoleucine and L-isoleucyl-L-leucine

New preparative procedures were developed applying tert-butoxycarbonyl or trifluoroacetyl protection of amino groups in the synthesis of L-leucyl-L-isoleucine and L-isoleucyl-L-leucine.

Champacyclin, a new cyclic octapeptide from Streptomyces strain C42 isolated from the Baltic Sea

New isolates of Streptomyces champavatii were isolated from marine sediments of the Gotland Deep (Baltic Sea), from the Urania Basin (Eastern Mediterranean), and from the Kiel Bight (Baltic Sea). The isolates produced several oligopeptidic secondary metabolites, including the new octapeptide champacyclin (1a) present in all three strains. Herein, we report on the isolation, structure elucidation and determination of the absolute stereochemistry of this isoleucine/leucine (Ile/Leu = Xle) rich cyclic octapeptide champacyclin (1a). As 2D nuclear magnetic resonance (NMR) spectroscopy could not fully resolve the structure of (1a), additional information on sequence and configuration of stereocenters were obtained by a combination of multi stage mass spectrometry (MSn) studies, amino acid analysis, partial hydrolysis and subsequent enantiomer analytics with gas chromatography positive chmical ionization/electron impact mass spectrometry (GC-PCI/EI-MS) supported by comparison to reference dipeptides. Proof of the head-to-tail cyclization of (1a) was accomplished by solid phase peptide synthesis (SPPS) compared to an alternatively side chain cyclized derivative (2). Champacyclin (1a) is likely synthesized by a non-ribosomal peptide synthetase (NRPS), because of high content of (D)-amino acids. The compound (1a) showed antimicrobial activity against the phytopathogen Erwinia amylovora causing the fire blight disease of certain plants.

DPP4 INHIBITOR AND PHARMACEUTICAL APPLICATION THEREOF

The present invention provides a Dpp4 inhibitor which comprises a leucine derivative of the following formula (1) or a methionine derivative of the following formula (2): wherein each R1 and R3 represents a hydrogen atom (H) and an L-amino acid residue; R2 represents a hydroxyl group (OH), alkoxy group having 1 to 6 carbon atoms, amino group (NH2), alkylamino group having 1 to 6 carbon atoms, glycine residue, β-alanine residue, L-amino acid (except for proline, alanine and phenylalanine) residue or L-amino-acid amide (except for proline amide, alanine amide and phenylalanine amide) residue; and R4 represents a hydroxyl group (OH), alkoxy group having 1 to 6 carbon atoms, amino group (NH2), alkylamino group having 1 to 6 carbon atoms, glycine residue, β-alanine residue, L-amino acid (except for proline and alanine) residue or L-amino-acid amide (except for proline amide and alanine amide) residue. These derivatives also act as autophagy regulators.